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Br J Pharmacol. 2019;176:1649–1663.Background and Purpose: The δ‐opioid receptor is an emerging target for the
management of chronic pain and depression. Biased signalling, the preferential
activation of one signalling pathway over another downstream of δ‐receptors,
may generate better therapeutic profiles. BMS 986187 is a positive allosteric
modulator of δ‐receptors. Here, we ask if BMS 986187 can directly activate the
receptor from an allosteric site, without an orthosteric ligand, and if a signalling bias
is generated.
Experimental Approach: We used several clonal cell lines expressing δ‐receptors,
to assess effects of BMS 986187 on events downstream of δ‐receptors by measuring
G‐protein activation, β‐arrestin 2 recruitment, receptor phosphorylation, loss of sur-
face receptor expression, ERK1/ERK2 phosphorylation, and receptor desensitization.
Key Results: BMS 986187 is a G protein biased allosteric agonist, relative to β‐
arrestin 2 recruitment. Despite showing direct and potent G protein activation,
BMS 986187 has a low potency to recruit β‐arrestin 2. This appears to reflect the
inability of BMS 986187 to elicit any significant receptor phosphorylation, consistent
with low receptor internalization and a slower onset of desensitization, compared
with the full agonist SNC80.
Conclusions and Implications: This is the first evidence of biased agonism medi-
ated through direct binding to an allosteric site on an opioid receptor, without a
ligand at the orthosteric site. Our data suggest that agonists targeting δ‐receptors,
or indeed any GPCR, through allosteric sites may be a novel way to promote signal-
ling bias and thereby potentially produce a more specific pharmacology than can be
observed by activation via the orthosteric site.1 | INTRODUCTION
Chronic pain and depression are two of the most common medical ail-
ments experienced worldwide and are often co‐morbid. For example,
an estimated 25% of the United States population (75 million people)
experience moderate‐to‐severe chronic pain (Reinke, 2014), whereas
an estimated 15–20% experience depression (Kessler & Bromet,dulator
wileyonlinelibrary.com/journ2013). Opioid analgesics that target the μ‐opioid receptor are the
most widely prescribed drugs for both chronic and acute pain but
suffer from serious side effects including respiratory depression and
abuse liability (McNicol et al., 2017; Przewłocki & Przewłocka,
2001). Treatments for depression are varied, but under the best
circumstances, only an estimated 50% of patients show full remission
(Rush et al., 2006). Mounting evidence suggests that agonists targeting
the δ‐opioid receptor, a GPCR, are effective in preclinical models of
chronic pain and depression and could provide for new therapies© 2019 The British Pharmacological Societyal/bph 1649
What is already known
• The δ‐receptor is a potential drug target for the
management of pain and depression.
• BMS 986197 is a positive allosteric modulator of the δ‐
receptor.
What this study adds
• BMS 986187 directly activates δ‐receptors via an
allosteric site.
• The direct δ‐receptor agonism of BMS 986187 is biased
for G‐protein activation over β‐arrestin recruitment.
What is the clinical significance
• δ‐receptor orthosteric agonists can be proconvulsant.
• Targeting δ‐receptors with a G‐protein‐biased allosteric
agonist may be a potentially safer therapeutic strategy.
1650 STANCZYK ET AL.BJP(Bie & Pan, 2007; Cahill, Holdridge, & Morinville, 2007; Jutkiewicz,
Kaminsky, Rice, Traynor, & Woods, 2005; Kabli & Cahill, 2007; Saitoh
& Yamada, 2012).
The development of δ‐receptor agonists, such as BW373U86,
SNC80, and related compounds, as medications has been limited due
to on‐target side effects, namely, a propensity to cause convulsions
and the rapid development of tolerance in both rodent and non‐
human primate models (Danielsson et al., 2006; Jutkiewicz et al.,
2005; Lutz & Brigitte, 2014; Pradhan, Smith, Kieffer, & Evans, 2012).
Until recently, all compounds developed as δ‐receptor agonists
targeted the orthosteric site on the receptor. However, the discovery
of allosteric modulators that act at δ‐receptors, in particular BMS
986187 (Burford, Livingston, et al., 2015), presents an opportunity
to interrogate this receptor in a novel way. An allosteric modulator is
a compound that binds to a site on a GPCR other than the orthosteric
site, where the endogenous ligand binds, and by doing so modulates
the affinity and/or efficacy of an orthosteric ligand. Allosteric modula-
tors can be positive (PAM), negative (NAM), or silent with regard to
their effect on orthosteric ligands (Conn, Christopoulos, & Lindsley,
2010; Keov, Sexton, & Christopoulos, 2011). Modulators may also
possess direct intrinsic pharmacological activity themselves. Such
compounds are commonly referred to as “ago‐PAMs” or “ago‐NAMs”
depending on the nature of this activity (Kenakin, 2007; Langmead &
Christopoulos, 2006).
One potential benefit of allosteric modulators is to engender
biased agonism or functional selectivity (Kenakin & Christopoulos,
2013). Biased agonism is the preferential activation, or inhibition, of
certain downstream signalling cascades over others, classically G‐
protein activation over β‐arrestin recruitment (Kenakin &
Christopoulos, 2013; Kenakin, Watson, Muniz‐Medina, Christopoulos,
& Novick, 2012; Schmid et al., 2017; Whalen, Rajagopal, & Lefkowitz,
2011). Thus, in theory, a drug could promote downstream effectors
associated with beneficial actions while bypassing the effectors
associated with the unwanted effects. Multiple studies have
suggested biased agonism stemming from orthosteric activation of
the δ‐receptors, although pertinent rigorous bias calculations are
rarely performed (Audet et al., 2008; see Pradhan et al., 2012).
Evidence suggests that β‐arrestin 2‐mediated internalization of the
δ‐receptors might be associated with some of the negative effects of
δ‐receptor agonists. Indeed, a number of ligands that fail to internalize
the δ‐receptors, such as ARM390, despite potent G‐protein activa-
tion, have shown reduced tolerance (Pradhan et al., 2009, 2010,
2012) and reduced propensity to cause convulsions (Pradhan, Befort,
Nozaki, Gavériaux‐Ruff, & Kieffer, 2011) in animal models. This sug-
gests an agonist that preferentially activates G‐protein over β‐arrestin
2 recruitment may have reduced on‐target side effects that have lim-
ited the utility of other δ‐receptor ligands, such as SNC80. However,
this does conflict with recent experiments in β‐arrestin knockout mice,
suggesting that β‐arrestin 2 recruitment does not contribute signifi-
cantly to the onset of convulsions (Dripps et al., 2017).
To date, no studies have examined the role played by allosteric
modulation in functional selectivity at the δ‐receptors. BMS 986187
shows probe dependence at the δ‐receptors, and our prior worksuggests it may be a directly acting allosteric agonist, as shown by its
ability to inhibit AC in the absence of an orthosteric agonist (Burford,
Livingston, et al., 2015; Burford, Traynor, & Alt, 2015). To this end, we
set out to elucidate the nature of this ago‐PAM activity. We found
that BMS 986197 was an allosteric agonist with biased signalling
towards G‐protein pathways over the recruitment of β‐arrestin 2.2 | METHODS
2.1 | Animals
All animal care and experimental procedures complied with the US
National Research Council's Guide for the Care and Use of Laboratory
Animals (National Research Council, 1996). Animal studies are
reported in compliance with the ARRIVE guidelines (Kilkenny, Browne,
Cuthill, Emerson, & Altman, 2010) and with the recommendations
made by the British Journal of Pharmacology. Male mice were used
for all experiments. C57BL/6N (RRID:MGI:5659255) mice were
obtained from Envigo (formerly Harlan, Indianapolis, IN, USA). The
Oprd1tm1Kff/J mouse strain (Oprd1tm1Kff/J, RRID:IMSR_JAX:007557)
was obtained from The Jackson Laboratory (Bar Harbor, ME, USA;
https://www.jax.org/strain/007557; Filliol et al., 2000). Mice were
group housed with a maximum of five animals per cage in clear poly-
propylene cages with corn cob bedding and nestlets as enrichment.
For breeding of the Oprd1tm1Kff/J mice, heterozygote pairs were
employed. Mice had free access to food and water at all times.
Animals were housed in pathogen‐free rooms maintained between
68°F and 79°F and humidity between 30% and 70% humidity with a
12‐hr light/dark cycle with lights on at 07:00 a.m.
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HEK (HEK293, RRID:CVCL_0045) cells stably expressing a tTA‐
dependent luciferase reporter and a β‐arrestin 2‐TEV fusion gene
(HTLA cells; Thermo Fisher Scientific) were maintained in DMEM
supplemented with 10% FBS, 1% penicillin, and 100 μg·ml−1 strepto-
mycin, 2 μg·ml−1 puromycin, and 100 μg·ml−1 hygromycin B at 37°C
and 5% CO2. HEK293 (ATCC Cat# CRL‐1573, RRID:CVCL_0045) cells
expressing N‐terminally FLAG‐tagged human δ‐receptors (HEK‐
hDOPr cells) were cultured in DMEM containing 10% FBS and 1%
penicillin and streptomycin and maintained in 0.8 mg·ml−1 G418. The
HEK‐hDOPr cells used for ERK1/ERK2 imaging studies were gener-
ated as previously described and maintained in DMEM supplemented
with 10% FBS (Shiwarski, Darr, Telmer, Bruchez, & Puthenveedu,
2017). CHO (ATCC Cat# CCL‐61, RRID:CVCL_0214) cells stably
expressing wild‐type human δ‐receptors (CHO‐hDOPr) were grown
in DMEM containing 10% FBS and 1% penicillin and streptomycin
and maintained in 0.4 mg·ml−1 G418 as previously described (Burford,
Livingston, et al., 2015; Burford, Traynor, & Alt, 2015).2.3 | Preparation of membrane homogenates
Cells were harvested, and membrane homogenates were prepared as
previously described (Clark, Harrison, Zhong, Neubig, & Traynor,
2003). Briefly, cells were washed with ice‐cold PBS, pH 7.4, and
detached from plates by incubation in harvesting buffer (0.68 mM
EDTA, 150 mM NaCl, and 20 mM HEPES at pH 7.4) and pelleted by
centrifugation at 200x g for 3 min. Cells were resuspended in ice‐cold
50 mM Tris (pH 7.4), homogenized using a Tissue Tearor (Dremel;
Mount Prospect, IL, USA), and centrifuged at 20,000x g at 4°C for
20 min. The pellet was then resuspended, homogenized, and centri-
fuged a second time. This final pellet was resuspended in ice‐cold
50 mM Tris (pH 7.4) and homogenized using a glass Dounce
homogeniser to give a protein concentration of 0.5–1.5 mg·ml−1 and
stored at −80°C. Protein concentration was determined using the
bicinchoninic acid quantification method (BCA assay) with BSA serving
as the standard.
For brain homogenates, mice (8 to 12 weeks of age) were killed by
cervical dislocation. Whole‐brain tissue, from the optic chiasmus
forward, was removed immediately and chilled in ice‐cold buffer
(50 mM Tris base, pH 7.4). Membrane homogenates were prepared
as previously described (Lester & Traynor, 2006). Final membrane
pellets were resuspended in 50 mM Tris base, pH 7.4, aliquoted, and
stored at −80°C. Protein content was determined using bicinchoninic
acid assay with BSA as the standard.2.4 | Stimulation of GTPγ35S binding
Agonist stimulation of GTPγ35S binding was measured as described
previously (Clark et al., 2003). Homogenates of HEK cells expressing
FLAG‐tagged‐human δ‐receptors, CHO cells expressing wild‐type
human δ‐receptors, or mouse brain (15–20 μg per well) wereincubated in “GTPγS buffer” (50 mM Tris–HCl, 100 mM NaCl, and
5 mM MgCl2, pH 7.4) containing 0.1 nM GTPγ
35S and 30 μM GDP
and varying concentrations of BMS 986187 or δ‐receptor agonists
for 1 hr in a shaking water bath at 25°C. The reaction was terminated
by vacuum filtration through GF/C filters using a Brandel harvester
and washed five times with ice‐cold GTPγS buffer. Filters were dried
and, following the addition of EcoLume scintillation cocktail, counted
in a Wallac 1450 MicroBeta Liquid Scintillation and Luminescence
Counter (PerkinElmer). The level of GTPγ35S binding was expressed
as fmol bound·mg−1 protein or by comparison with the full δ‐receptor
agonist SNC80 at 10 μM to account for variability between membrane
preparations.
2.5 | Internalization of δ‐receptors
As described previously (Bradbury, Zelnik, & Traynor, 2009), FLAG‐
tagged HEK‐hDOPr cells were plated at a density of 0.5 × 106 cells
per well in poly‐D‐lysine‐coated, 24‐well plates. When cells reached
80% confluency, they were treated with vehicle (1% DMSO) or indi-
cated drugs and rocked at room temperature for the indicated times.
Cells were then washed three times with ice‐cold tris‐buffered saline
(TBS) and fixed with 3.7% paraformaldehyde in TBS at room tempera-
ture for 15 min. After fixing, cells were washed three times with cold
TBS and blocked at room temperature with 1% BSA inTBS for 60 min.
Following block, cells were washed two times with TBS and incubated
with FLAG M2‐Alkaline Phosphatase Antibody at a 1:625 dilution for
60 min. Cells were then washed five times with TBS and treated with
p‐nitrophenylphosphate for 8 min. The reaction was stopped with 3 N
NaOH, and 200 μl from each well was transferred to a 96‐well plate
for reading at 405 nm on VERSAmax tunable microplate reader
(Molecular Devices, Sunnyvale, CA, USA). The percentage of internal-
ized receptors was determined as loss of surface receptors using the
following equation: [1 − (Drug OD − Background OD/Control
OD − Background OD) × 100]. Background was determined as the
absorbance of non‐transfected HEK cells, and control was the absor-
bance of cells incubated in the absence of drug.
2.6 | β‐Arrestin 2 recruitment
2.6.1 | Confocal microscopy
Recruitment of β‐arrestin 2 in FLAG‐tagged HEK‐DOPr cells was per-
formed as described previously (Bradbury et al., 2009). Briefly, cells
were seeded into 24‐well plates containing poly‐D‐lysine‐coated glass
coverslips. Cells were transfected using Lipofectamine 2000 with
0.4 μg of β‐arrestin 2‐GFP cDNA and incubated for 48 hr, then
treated with vehicle, 10 μM SNC80, or 10 μM BMS 986187 for
5 min. Following fixation with 3.7% paraformaldehyde, cells were
incubated with M2 mouse anti‐FLAG primary antibody followed by
AlexaFluor 594 goat anti‐mouse secondary antibody. Images were
obtained using a NikonA1R confocal microscope and quantified using
ImageJ software (National Institutes of Health; ImageJ, RRID:
SCR_003070).
1652 STANCZYK ET AL.BJP2.6.2 | PRESTO‐TANGO arrestin recruitment
For the PRESTO‐TANGO assay, HTLA cells at 15,000 cells per well
were transfected with plasmids (20 ng) encoding FLAG‐tagged
hDOPr‐TANGO (OPRD1‐TANGO; Thermo Fisher Scientific) using
Lipofectamine 2000 and plated in Greiner Bio‐One cell culture micro-
plates. After 24 hr, cells were treated with the indicated drug at the
indicated concentrations. After 48 hr, One‐Glo solution was added
to each well, and luminescence was measured using a Pherastar plate
reader (BMG Labtech, Germany). Data were normalized to per cent of
standard full agonist (10 μM SNC80) to account for variability
between assays in plating and transfection efficiency.2.7 | ERK1/ERK2 phosphorylation
HEK293 cells stably expressing FLAG‐tagged human δ‐receptors were
transiently transfected with the ERK activity reporter cEKAR (Fritz
et al., 2013). ERK activity in response to SNC80 and BMS 986187
was assessed as previously described (Weinberg, Zajac, Phan,
Shiwarski, & Puthenveedu, 2017). Briefly, cells were plated at low den-
sity, allowed to grow for 2 days, and then serum starved for 4 hr. Cells
were labelled with Alexa Fluor 647 antimouse M1 antibody for
10 min. Single‐cell fluorescence for cyan fluorescent protein (405‐
nm excitation, 470/50 emission filter), FRET (405‐nm excitation,
530lp emission filter), and M1 (647‐nm excitation, 700/75 emission)
was collected every 30 s for 22.5 min, with addition of drug (1 μM
SNC80 or 10 μM BMS 986187) occurring after 2.5 min of no‐
treatment baseline. The ratio of FRET to cyan fluorescence protein
fluorescence was calculated for each cell on a frame‐by‐frame basis
and normalized to the average ratio during baseline. For calculating
total response, the mean AUC was taken for the vehicle condition,
and that mean was subtracted from the individual AUC for each cell
in the treatment conditions. Each experiment was conducted using
the same batch of transiently transfected cells from the same stable
cell line and passage number and carried out on the same day under
all conditions (vehicle, SNC80, and BMS 986187) to ensure that any
nonresponding cells were represented equally across treatment
conditions.2.8 | Western blot for phospho‐Ser363
As described previously (Bradbury et al., 2009), HEK cells stably
expressing FLAG‐tagged human δ‐receptors were plated at a density
of 0.5 × 106 cells per well in poly‐D‐lysine‐coated, 24‐well plates,
and experiments were performed when cells were at 80% confluency.
Cells were treated with vehicle (1% DMSO), TAN‐67, DPDPE, SNC80,
or BMS 986187 for 1 hr. Cells were then rinsed with PBS, and lysates
were collected with RIPA (50 mM Tris, pH 7.4, 150 mM NaCl, 1%
Triton X‐100, 1% sodium deoxycholic acid, and 0.1% sodium dodecyl
sulfate [SDS]) plus protease inhibitor cocktail, 2 mM EDTA, 100 mM
NaF, 100 mM phenylmethanesulfonyl fluoride, and 10 mM sodium
orthovanadate. Lysates were then sonicated briefly and centrifugedat 10,000x g for 10 min. Equal amounts of protein samples were diluted
in SDS sample buffer (62.5 mM Tris–HCl, pH 6.8, 2% SDS, 10%
glycerol, and 0.0008% bromophenol blue) and β‐mercaptoethanol,
loaded onto 10% polyacrylamide gels. Following transfer to
nitrocellulose, membranes were blocked for 1 hr with 5% nonfat dried
milk in PBS then incubated with 1:1,000 dilution of rabbit anti‐
phosphorylated δ‐receptor antibody overnight at 4°C. Membranes
were washed and incubated with 1:10,000 HRP–goat antirabbit IgG
for 1 hr. To probe total FLAG‐tagged δ‐receptors, the membranes were
stripped using mild stripping buffer (distilled water, pH 2.2, 1.5%
glycine, 0.1% SDS, and 1% Tween 20), washed, then blocked with 5%
nonfat dried milk for 1 hr. Following block, membranes were incubated
with 1:1,000 mouse anti‐FLAG for 1 hr in 5% nonfat dried milk, TBS
Tween containing 1 mM CaCl2. Membranes were washed and treated
with 1:10,000 HRP–goat anti‐mouse IgG for 1 hr. Following washing,
membranes were treated with 1:1 SuperSignal chemiluminescent sub-
strate, and bands were detected using the EpiChemi3 darkroom
(UVP, Upland, CA, USA). Band intensity was quantitated using ImageJ
(National Institutes of Health) and normalized to total human
δ‐receptors, as determined by FLAG staining, to account for any differ-
ences in total protein.2.9 | Receptor desensitization
Desensitization was determined by incubating CHO‐hDOPr cells with
either vehicle or drug for indicated time periods at 37°C. Following
incubation, cells were washed five times with PBS, and membranes
were prepared as described above. For the time course of desensitiza-
tion, maximum GTPγ35S binding was measured using 10 μM SNC80 in
vehicle‐treated cells; drug treated conditions were expressed as per
cent of this maximal binding. For concentration response, GTPγ35S
binding elicited by SNC80 was measured in membranes pretreated
with 500 nM SNC80, 10 μM BMS 986187, or vehicle for 30 min
and expressed as fmol bound·mg−1 of protein.2.10 | Data and statistical analyses
The data and statistical analysis comply with the recommendations of
the British Journal of Pharmacology on experimental design and analysis
in pharmacology. All in vitro assays were a mean of at least five sepa-
rate preparations, except where stated, and each was run in duplicate
or triplicate as shown in the relevant figure legend, to ensure the
reliability of the single values. None of the in vitro biochemical
experiments were performed or analysed in a blinded manner.
Data were graphed as individual experiments for analyses unless
otherwise stated, and statistical analysis was performed using
Graphpad Prism 6.5. Concentration–effect curves were analysed using
a three‐parameter curve fit with Hill slopes set to 1.0. Maximal values
were not constrained; minimum values were constrained to zero if
contained in the 95% confidence intervals. For internalization, the
GTPγ35S assay, and confocal microscopy, one‐way ANOVA was per-
formed, and Tukey post hoc test for multiple comparisons was applied
STANCZYK ET AL. 1653BJPif F was significant. The desensitization time course was analysed by
two‐way ANOVA. Bias calculations were performed as described by
Kenakin (2017) as follows: For each ligand and respective response,
individual experimental curves were used to calculate log(max/EC50).
The difference in log(max/EC50) between arrestin recruitment and
GTPγ35S, Δlog(max/EC50), was then calculated. Individual results were
combined to give means ± SEM values shown in Table 1. Finally, the
differences between the Δlog(max/EC50) values for the reference
ligand (SNC 80) and test ligand were calculated to give a ΔΔlog(max/
EC50) values, the antilog of which is the bias factor. For all analyses,
significance was set at 5% (0.05 P value).2.11 | Materials
Guanosine‐5′‐O‐(3‐[35S]thio)triphosphate (GTPγ35S) and [3H]
diprenorphine were from PerkinElmer Life and Analytical Sciences
(Boston, MA, USA). BMS 986187 was synthesized and characterized
as previously described (Burford, Livingston, et al., 2015; Burford,
Traynor, & Alt, 2015). Naltrindole (NTI), naloxone, TAN‐67, DPDPE,
SNC80, protease inhibitor cocktail, GDP, p‐nitrophenyl phosphate,
M1 mouse anti‐FLAG antibody (Cat# F3040, RRID:AB_439712), and
M2 mouse anti‐FLAG antibody conjugated to alkaline phosphatase
(Cat# A9469, RRID:AB_439699) were from MilliporeSigma (St Louis,
MO, USA). Goat anti‐rabbit (Cat# sc‐2004, RRID:AB_631746) or
mouse (Cat# sc‐2005, RRID:AB_631736) antibodies conjugated to
HRP were from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and
rabbit anti‐phospho‐Ser363‐ δ‐receptor antibody (Cat# 3461, RRID:
AB_2768155) from Cell Signaling (Danvers, MA, USA). β‐Arrestin 2‐
GFP cDNA was a gift from Marc Caron (Duke University, Durham,
NC, USA). Poly‐D‐lysine‐coated 24‐well plates and poly‐D‐lysine‐
coated 12‐mm, no. 1 coverslips were from BD Biosciences (San Jose,
CA, USA). EcoLume scintillation cocktail and ultrapure formaldehyde
were obtained from MP Biomedicals (Aurora, OH, USA) and
Polysciences Inc. (Warrington, PA, USA) respectively. ProLong Gold
antifade reagent, Alexa 594 goat anti‐mouse IgG (Thermo Fisher Scien-
tific, Cat# A‐11032, RRID AB_2534091), and Lipofectamine 2000were
from Invitrogen (Carlsbad, CA, USA). One‐Glo solution was purchased
from Promega (Madison, WI, USA). SuperSignal chemiluminescent
substrate was purchased fromThermo Fisher (Waltham, MA, USA).TABLE 1 Summary of bias calculations
Ligand
β‐Arrestin 2 Bias (towards G‐protein)
Max EC50 (nM) Arrestin/G‐protein fold EC5
SNC80 1 353 ± 141 18.6
BMS 986187 1a 578,500 ± 419,100 1787
0.5a 238,179 ± 188,400 737
DPDPE 1 16,100 ± 805 85
Calculations were performed from the data generated in Figure 5, as described
aIn order to extrapolate an accurate EC50 value for BMS 986187‐mediated arre
recruitment by SNC80 or 0.5, assuming the maximum value is that observed a2.12 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org,
the common portal for data from the IUPHAR/BPS Guide to
PHARMACOLOGY (Harding et al., 2018), and are permanently
archived in the Concise Guide to PHARMACOLOGY 2017/18
(Alexander et al., 2017).3 | RESULTS
3.1 | BMS 986187 stimulates binding of GTPγ35S by
δ‐receptors
BMS 986187 has been shown to produce inhibition of forskolin‐
stimulated cAMP production in the absence of orthosteric ligand,
demonstrating that it has direct agonist action via an allosteric site
(Burford, Livingston, et al., 2015; Burford, Traynor, & Alt, 2015). How-
ever, inhibition of AC is a highly amplified signalling output and
requires low efficacy in a compound, although it does require prior
stimulation of heterotrimeric Gαi/o proteins. To demonstrate that
BMS 986187 can directly stimulate δ‐receptors to activate Gαi/o, we
performed GTPγ35S‐binding assays as previously described (Traynor
& Nahorski, 1995) in HEK293 cells expressing human‐δ‐receptors
(Figure 1a). BMS 986187 stimulated GTPγ35S binding in a
concentration‐dependent manner, giving a potency value (EC50) of
301 ± 85 nM. significantly less potent than SNC80 (19 ± 11nM). In
brain homogenates from C57/BL6 mice, the δ‐receptor full agonist
SNC80 produced GTPγ35S binding with an EC50 of 203 ± 31 nM
(Figure 1b). BMS 986187 also stimulated GTPγ35S binding with a
significantly lower potency (EC50 of 1681 ± 244 nM), but the maximal
GTPγ35S response to BMS 986187 was 38% greater than that
produced by SNC80, although this difference did not reach
significance. To confirm the response to BMS 986187 was due to acti-
vation of δ‐receptors, we repeated the experiments in brain tissue
from δ‐receptor knockout mice. In brain homogenates from these
mice, a small degree of BMS 986187‐stimulated GTPγ35S
binding remained, representing 20% of the BMS 986187 response
observed in tissue from wild‐type mice, with an EC50 of
600 ± 397 nM. In contrast, SNC80 produced no appreciableGTPγ35S
0 shift ΔΔlog(Max/EC50) Bias factor EC50 (nM) Max
0 1 19.0 ± 6 1
1.91 ± 0.7 81 323 ± 96 0.92 ± 0.03
1.53 ± 0.82 34
1.03 ± 0.67 11 189 ± 25 0.85 ± 0.09
in Section 2 to determine ΔΔlog(max/EC50) (Kenakin, 2017).
stin recruitment, the Emax was constrained to 1, equivalent to the level of
t the point of solubility (Figure 5b).
FIGURE 1 BMS 986187 elicits G‐protein activation. The capacity
for increasing concentrations of BMS 9861897 and SNC80 to
increase GTPγ35S binding was measured in (a) membranes from FLAG‐
tagged HEK‐hDOPr cells or in (b) brain homogenates from wild‐type
or δ‐receptor knockout (KO) mice. Data are presented as percentage
of the response to a maximal concentration (10 μM) of SNC80. All
plotted points are the means ± SEM of five independent experiments,
each run in duplicate. *P<0.05, BMS 986187 concentration‐response
curves significantly different from SNC80 concentration‐response
curves, as determined by one‐ (A) or two‐ (B) way ANOVA with
Dunnett's post hoc test
1654 STANCZYK ET AL.BJPbinding over baseline in δ‐receptor knockout mice. These findings sug-
gest that BMS 986187 activates G‐protein through the δ‐receptors at
physiological receptor expression levels while also eliciting a very low
level of G‐protein activation through a non‐δ‐receptor‐mediated
pathway.FIGURE 2 Antagonists show non‐competitive interaction with BMS
986187. (a) Antagonists naltrindole (NTI) and naloxone (NLX) reduce
maximal GTPγ35S binding caused by BMS 986187 in FLAG‐tagged
HEK‐hDOPr cells, normalized to per cent of effect of 10 μM SNC80 to
control for variation between the different preparations. *P<0.05,
significantly different from BMS 986187 with vehicle, as determined
by one‐way ANOVA with Tukey's post hoc test. (b) GTPγ35S
concentration response curves for BMS 986187 with increasing NTI
concentrations. *P<0.05, significantly different from BMS 986187 +
vehicle as determined by two‐way ANOVA withTukey's post hoc test.
(c) GTPγ35S binding concentration response of NTI with fixed
concentration BMS 986187 (10 μM) or SNC80 (1 μM), in CHO cells
expressing human δ‐receptors. *P<0.05, significantly different from
SNC80 as determined by two‐way ANOVA withTukey's post hoc test.
All plotted points are the mean ± SEM of (b, c) 5 or (a) 10 individual
experiments, each performed in duplicate3.2 | BMS 986187 stimulates GTPγ35S binding
through an allosteric site on δ‐receptors
Previous work has shown that BMS 986187 does not displace the
antagonist 3H‐diprenorphine bound to the orthosteric site (Burford,
Livingston, et al., 2015; Burford, Traynor, & Alt, 2015). To confirm that
the agonist action of BMS 986187 was not due to interaction at the
orthosteric site, GTPγ35S binding was performed in membranes from
HEK‐hDOPr cells in the presence or absence of various concentra-
tions of orthosteric antagonists. The δ‐receptor antagonist NTI
(100 nM) reduced the maximal GTPγ35S binding evoked by 10 μM
BMS 986187 from 99 ± 6% to 51 ± 17% (Figure 2a). Increasing the
concentration of NTI by 100‐fold (to 10 μM) caused no additional
inhibition of BMS 986187‐stimulated GTPγ35S binding (50 ± 4%;
Figure 2a). NTI (10 μM) alone failed to produce any appreciable
stimulation of GTPγ35S binding, consistent with its classification as a
neutral antagonist (Tryoen‐Toth et al., 2005). The partial loss of BMS
986187‐stimulated GTPγ35S binding was also observed in the pres-
ence of 10 μM of the non‐specific opioid antagonist naloxone. UsingCHO‐hDOPr cells as an alternative cell line, NTI showed a
concentration‐dependent, but saturable, inhibition of BMS 986187
stimulation of GTPγ35S binding with the lack of parallel shifts
confirming the agonist action of the modulator is not due to
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cooperativity between the orthosteric and allosteric sites. To further
confirm this, we evaluated the effect of increasing concentrations of
NTI on the maximal stimulation elicited by BMS 986187 and SNC80
using membranes from CHO‐hDOPr cells (Figure 2c). NTI showed a
saturable inhibition of BMS 986187 stimulation of GTPγ35S binding.
In contrast, SNC80‐mediated stimulation of GTPγ35S binding was fully
inhibited by NTI, consistent with a competitive mechanism.FIGURE 3 Internalization of δ‐receptors. Receptor internalization by
δ‐receptor ligands in FLAG‐tagged HEK‐hDOPr cells. (a) Preliminary
time‐course studies (means ± SEM, n = 3 experiments in triplicate)
with 10 μM concentrations of ligands were to identify an appropriate
time (1 hr) to determine (b) concentration–response studies for the
different δ‐receptor ligands (means ± SEM, n = 5 experiments in
triplicate). The symbols in (a) also refer to (b)3.3 | BMS 986187 causes a low level of δ‐receptor
internalization
Previous studies of the δ‐receptors suggest that ligands with high
efficacy at activating G‐protein while maintaining low efficacy at pro-
moting receptor internalization show reduced tolerance in animal
models (Pradhan et al., 2009). To this end, we next sought to determine
whether BMS 986187 would cause internalization of δ‐receptors
relative to the orthosteric partial agonists TAN‐67 and DPDPE and
the full agonist SNC80. Preliminary studies indicated that 10 μMwould
be a maximal effect for all ligands, and from initial time‐course studies
(Figure 3a), we chose 1 hr to evaluate and compare the ligands. Due to
the small effect window, data were pooled for analysis to provide max-
imum and EC50 values with 95% confidence intervals. BMS 986187
treatment resulted in low levels of internalization (7 [3.9–10.0] %)
relative to TAN‐67 (11 [5.2–16.2] %) < DPDPE (31 [17.7–44.1] %)
and SNC80 (33 [24.7–40.9] %) with a potency order TAN‐67
(1.3 [0.15–11.0] nM) = SNC80 (3.7 [1.5–9.2] nM) > BMS968187 (94
[59–1007] nM) = DPDPE (212 [72–623] nM).
To contrast the propensity of BMS 986187 to cause internalization
with its ability to activate G‐protein at δ‐receptors, we measured the
maximal GTPγ35S binding by BMS 986187 and compared this with
saturating concentrations (10 μM) of the partial agonist peptide
DPDPE, the partial agonist TAN‐67, and the full agonist SNC80, which
was used as the standard. As shown in Figure 4b, BMS 986187 elic-
ited 99 ± 6% of GTPγ35S binding relative to SNC80 versus 63 ± 7%
and 75 ± 6% for TAN‐67 and DPDPE respectively. Thus, BMS
986187 gives a greater level of G‐protein activation than DPDPE
but a reduced level of internalization. Additionally, BMS 986187
affords a level of internalization similar to that after TAN‐67, but stim-
ulates a higher level of GTPγ35S binding.3.4 | BMS 986187 is G‐protein‐biased, relative to
β‐arrestin 2 recruitment
The fact that BMS 986187 affords greater GTPγ35S stimulation that
DPDPE and TAN‐67 while causing a low level of δ‐receptor internali-
zation is indicative of ligand bias. Internalization of receptors is largely
β‐arrestin dependent. In order to explore this further, we directly com-
pared concentration responses for BMS 986187 and SNC80 to recruit
β‐arrestin 2 to δ‐receptors and stimulate GTPγ35S binding. BMS
986187 and SNC80 stimulated a similar level of GTPγ35S binding in
HEK‐hDOPr cells (Figure 5b), in agreement with our previous result,(Figure 1a) although BMS 986187 was less potent (Table 1). In
contrast, using the PRESTO‐TANGO assay, BMS 986187 recruited
β‐arrestin 2 very weakly up to 100 μM, the limit of solubility
(Figure 5a). Extrapolation of the BMS 986187 concentration–
response curve assuming a similar maximum to SNC80 afforded an
EC50 for BMS 986187 of 579 μM. In comparison, TAN‐67 and
DPDPE recruited similar levels of β‐arrestin 2 as SNC80, although
DPDPE (16.1 ± 8.0 μM) was much less potent than TAN‐67
(327 ± 176 nM) or SNC80 (353 ± 141 nM). From these data, the
relative bias of BMS 986187 for GTPγ35S stimulation over β‐arrestin
2 recruitment was evaluated with SNC80 serving as a reference
agonist using the log(max/EC50) function as described by Kenakin
(2017; Table 1). This shows BMS 986187 is G‐protein biased,
relative to β‐arrestin 2, when compared with SNC80, with a bias fac-
tor of 82 (Table 1). It should be noted that the PRESTO‐TANGO
assay employs a chimeric δ‐receptor with a vasopressin receptor tail,
although the effect of this modification should be eliminated by
using SNC80 as a reference ligand (Kenakin, 2017). Utilizing this
FIGURE 4 BMS 986187 shows biased activation of GTPγ35S relative to receptor internalization. δ‐receptor ligands were evaluated in FLAG‐
tagged HEK‐hDOPr cells by measuring (a) receptor internalization or (b) stimulation of GTPγ35S bound. BMS 986187 showed significantly
lower internalization relative to DPDPE and SNC80, despite showing significantly greater GTPγ35S binding relative to TAN‐67 and DPDPE.
GTPγ35S binding is normalized as per cent of 10 μM SNC80 to control for variation between the different preparations. All experiments were
performed using saturating concentrations of compounds (10 μM). Data are expressed as mean ± SEM of 5 (internalization) or 10 (GTPγ35S)
individual experiments, each performed in duplicate. *P<0.05, significantly different from BMS 986187 as determined by one‐way ANOVA with
Tukey's post hoc test
FIGURE 5 BMS 986187 is G‐protein biased over β‐arrestin 2. BMS
986187 bias was evaluated between (a) β‐arrestin 2 recruitment and
(b) GTPγ35S binding relative to the standard orthosteric agonist
SNC80. Normalization was performed to control for sources of
variation across preparation and to allow for comparison across both
assays. β‐Arrestin assays were performed in HTLA cells transiently
transfected with hDOR‐TANGO and GTPγ35S assays in membranes
from FLAG‐tagged HEK‐hDOPr cells, as described in Methods . Data
are presented as the mean of five (GTPγ35S) or seven (β‐arrestin 2)
independent experiments, each performed in duplicate and expressed
as mean ± SEM
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with SNC80 with a calculated bias factor of 11 (Table 1). This is
similar to the bias of DPDPE compared with SNC80 of 6, calculatedusing the same equation from data in Chiang, Sansuk, and van Rijn
(2016), who employed a complementation assay for β‐arrestin
recruitment in CHO cells. Moreover, the bias of BMS 986187
fits with the change in ligand order when comparing internalization
with GTPγ35S binding (Figure 4), and the PRESTO‐TANGO
assay has been previously used in studies of receptor bias (Che
et al., 2018).
To confirm the low degree of β‐arrestin 2 recruitment to δ‐
receptors by BMS 986187, we performed confocal microscopy in
FLAG‐tagged HEK‐DOPr cells transfected with 0.4 μg β‐arrestin 2
GFP as shown in Figure 6. Cells were incubated for 5 min with
10 μM of either SNC80 or BMS 986187, a saturating concentration
for G‐protein activation. β‐Arrestin 2 localization was then quantified
as a ratio of fluorescent intensity at the cell membrane divided by
the cytoplasmic intensity using line scan analysis. Consistent with
the findings in Figure 5b and published literature (Chiang et al.,
2016), SNC80 afforded significant translocation of β‐arrestin 2 to
the plasma membrane, whereas localization in cells treated with
BMS 986187 was not significantly different from baseline. This sug-
gests the maximal β‐arrestin 2 recruitment in response to BMS
986187 is much less than recruited by SNC80, so we recalculated
the bias factor assuming the 100 μM data point in Figure 5a (the point
of solubility) was the maximal effect; this calculation yielded a bias fac-
tor of 34 (Table 1).3.5 | BMS 986187 shows low levels of ERK1/ERK2
activation
Agonists at opioid receptors have been shown to signal through
ERK1/ERK2 via both G‐protein‐ and β‐arrestin‐mediated pathways,
and previous work has shown that BMS 986187 acting as a PAM
can increase the potency of orthosteric δ‐receptor agonists in promot-
ing ERK1/ERK2 phosphorylation (Burford, Livingston, et al., 2015;
FIGURE 6 Effect of SNC80 and BMS
986187 on β‐arrestin 2 recruitment. FLAG‐
tagged HEK‐hDOPr cells were transfected
with 0.4 μg β‐arrestin 2 GFP and treated with
10 μM of either SNC80 or BMS 986187 for
5 min and imaged using confocal microscopy.
FLAG‐tagged δ‐receptors are represented in
the red channel with the green channel
representing β‐arrestin 2. (a) Representative
images and (b) β‐arrestin 2 recruitment
expressed as surface/cytoplasmic GFP
intensity. Data represent the means ± SEM of
34 cells per condition from five independent
drug treatments. *P<0.05, significantly
different from control and BMS 986187 as
determined by one‐way ANOVA with Tukey's
post hoc test
STANCZYK ET AL. 1657BJPBurford, Traynor, & Alt, 2015). However, BMS 986187 (10 μM) alone
failed to elicit significant ERK1/ERK2 phosphorylation relative to vehi-
cle in HEK‐hDOPr cells, whereas SCN80 (1 μM) afforded robust phos-
phorylation of ERK1/ERK2 (Figure 7). As expected, we observed
SNC80‐promoted δ‐receptor internalization (Figure 7a) and we also
saw internalization at later time points in approximately 50% of cells
treated with BMS 986187 (Figure 7a). A similar percentage of
vehicle‐treated cells showed δ‐receptor internalization, although to a
lesser degree than BMS 986187, suggesting that the modulator is
promoting constitutive internalization of δ‐receptors in these cells(Ong, Xue, Olmstead, & Cahill, 2015; Trapaidze, Gomes, Bansinath, &
Devi, 2000). This agrees with the BMS 986187‐induced enhancement
of δ‐receptor internalization shown in Figure 3.3.6 | BMS 986187 induces low levels of
phosphorylation and desensitization in δ‐receptors
Phosphorylation, arrestin recruitment, and receptor internalization
of δ‐receptors are initiated by a phosphorylation event at Ser363
FIGURE 7 BMS 986187 elicits low ERK1/ERK2 phosphorylation. (a) Example montage of cytoplasmic ERK response in FLAG‐tagged HEK‐
hDOPr cells in response to 1 μM SNC80. Top row: FLAG‐tagged δ‐receptors labelled with Alexa647‐conjugated M1 antibody. Bottom row:
ratio of FRET/cyan fluorescence protein (CFP) fluorescence of expressed cEKAR sensor. Agonist added at 2.5 min. Scale bar is 20 μm, frames
every 4 min. (b) Representative montage of cytoplasmic ERK response measured in HEK‐hDOPr cells, in response to 10 μM BMS 986187. (c)
Average ERK response over time of HEK‐hDOPr cells treated with 1 μM SNC80 (n = 47 cells), 10 μM BMS 986187 (n = 34 cells), or vehicle (n = 39
cells). Responses are represented as fractional change over baseline. Solid line is the mean response, and shaded region inside dotted lines
represents ± SEM. (d) SNC80 produced a significantly higher total ERK response compared with BMS 986187. Total response is measured as AUC
of treatment condition minus AUC of vehicle. Values shown are means ± SEM. *P<0.05, significantly different as determined by unpaired two‐
tailed t‐test
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Law, 2007). As BMS 986187 promotes only a low level of receptor
internalization or β‐arrestin 2 recruitment, we hypothesized this was
due to inefficient phosphorylation of this residue. To assess this, we
performed Western blot analysis for Ser363 phosphorylation of
FLAG‐tagged δ‐receptors expressed in HEK293 cells treated withvarious δ‐receptor agonists for 1 hr as shown in Figure 8. Consistent
with the internalization data, BMS 986187 did not induce significant
phosphorylation of this residue compared with the vehicle control.
Similar findings were seen with TAN‐67, whereas the higher
internalizing agonists DPDPE and SNC80 caused a marked degree
of phosphorylation.
FIGURE 8 BMS 986187 poorly phosphorylates Ser363 on δ‐
receptors. (a) Western blot of membranes from FLAG‐tagged HEK‐
hDOPr cells, incubated with 10 μM concentrations of various δ‐
receptor ligands probed for phosphorylated Ser363. (b) Data are
expressed as a ratio of phosphorylated receptor to total receptor
(FLAG). Each column is the mean of five independent
experiments ± SEM. *P<0.05, significantly different from vehicle as
determined by one‐way ANOVA with Tukey's post hoc test FIGURE 9 BMS 986187 treatment produces significantly less loss of
agonist activity at δ‐receptors than SNC80. (a) CHO‐hDOPr cells were
pretreated with either 500 nM SNC80 or 10 μM BMS 986187 for the
indicated times, and then membrane homogenates were prepared as
described in Section 2. The level of GTPγ35S binding induced by a
challenge with 10 μM SNC80 in the membranes was determined and
plotted against the time of cell pretreatment with SNC80 or BMS
986187. (b) CHO‐hDOPr cells were pretreated as above with SNC80
or BMS 986187 for 30 min, membranes homogenates were prepared,
and SNC80 concentration response curves for stimulation of GTPγ35S
binding were constructed. Data are expressed as % of maximum
binding in untreated cells ± SEM from five independent experiments,
each performed in duplicate. *P<0.05, significantly different from
SNC80 as determined by two‐way ANOVA withTukey's post hoc test
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phorylation, arrestin recruitment, and internalization, we predicted
there would be a reduced desensitization of δ‐receptors, measured
as a loss of receptor signalling, when cells were treated with BMS
986187 compared with SNC80. CHO‐hDOPr cells were incubated
for varying times with equipotent concentrations (as determined by
GTPγ35S binding, Figure 1) of 10 μM BMS 986187 or 500 nM
SNC80. Membranes homogenates were then prepared, and GTPγ35S
binding was determined following a challenge with a maximal concen-
tration (10 μM) of SNC80. Membranes from cells pretreated with
SNC80 or BMS 986187 showed a reduction in the maximal GTPγ35S
response, but the loss was more rapid for SNC80 (Figure 9), such that
a 1 hr pretreatment with SNC80 resulted in a 86% loss compared with
only a 39% loss with BMS 986187. Likewise, preincubation of cells for
30 min with BMS 986187 caused a lesser effect on the concentration
response curve for SNC80 (maximum response = 68 ± 7%;
EC50 = 7.4 ± 1.6 nM) than preincubation with SNC80 (maximal
response = 31 ± 7%; EC50 = 25 ± 3.5 nM).4 | DISCUSSION
The data presented indicate that BMS 986187 is a biased allosteric
agonist at the δ‐receptor, giving a maximal response in the GTPγ35S
assay of equivalent magnitude to that seen with the orthosteric fullagonist SNC80, albeit BMS 986187 is considerably less potent. In
contrast to this strong response observed in G‐protein activation,
BMS 986187 did not significantly recruit β‐arrestin 2. This is a con-
sequence of low levels of receptor phosphorylation and leads to a
low level of receptor internalization and desensitization. When
compared with SNC80, BMS 986187 is significantly biased towards
G‐protein activation, relative to the recruitment of β‐arrestin 2. This
is the first evidence of an allosteric agonist displaying bias at an opi-
oid receptor.
The direct agonist activity of BMS 986187 in the GTPγ35S assay in
HEK‐DOPr cells agrees with the results from the original report of
PAMs at δ‐receptors, using AC inhibition in CHO cells as a readout
(Burford, Livingston, et al., 2015; Burford, Traynor, & Alt, 2015). The
allosteric nature of the observed agonism was suggested by the
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diprenophine (Burford, Livingston, et al., 2015; Burford, Traynor, &
Alt, 2015). In the present study, we confirmed that BMS 986187 ago-
nist activity occurred via binding to an allosteric site because the
orthosteric antagonists NTI and naloxone only partly inhibited the
ability of BMS 986187 to stimulate GTPγ35S binding, and increasing
concentrations of the NTI did not give parallel shifts in the BMS
986187 concentration–response curve. This confirms that agonism
can be mediated by sites on the receptor other than the orthosteric
site and demonstrates an indirect interaction between the allosteric
and the orthosteric sites. Although these results in transfected HEK
cells are encouraging, δ‐receptors in these cells are expressed at
supraphysiological levels, which may not translate to relevant in vivo
agonism (Kelly, 2013; Langmead & Christopoulos, 2006). Using mouse
brain homogenates, we confirmed that the level of G‐protein activa-
tion elicited by BMS 986187 was similar to that of the full agonist,
SNC80. However, these data also indicated that BMS 986187 was
not completely selective for δ‐receptors, because the same assay
performed using mouse brain homogenates from δ‐receptor knockout
mice still afforded a low level of GTPγ35S stimulation.
Previous work has indicated that BMS 986187 can act as a PAM for
the μ‐ and κ‐opioid receptors, although no significant direct ago‐
PAM activity has so far been detected at either of these receptors
(Livingston et al., 2018). Alternatively, BMS 986187 could be acting
at another, so far unidentified, GPCR.
Despite stimulating a higher level of GTPγ35S binding than the pep-
tidic δ‐receptor agonist DPDPE, BMS 986187 produced significantly
lower receptor internalization. Thus, maximal G‐protein stimulation
was in the order BMS 986187 = SNC80 > DPDPE > TAN‐67, whereas
maximal internalization was in the order SNC80 = DPDPE > TAN‐
67 = BMS 986187. This striking change of order of maximal effect
across the two different signalling outputs using the same cell line
indicates the bias resulting from BMS 986187 occupancy of its alloste-
ric binding site. We confirmed this finding by calculating the degree of
bias for the signalling preference of BMS 986187‐occupied δ‐receptors
for G‐protein activation over β‐arrestin 2 recruitment, compared with
SNC80 as a reference ligand. The very low level of β‐arrestin 2 recruit-
ment by BMS 986187 was confirmed by the lack of observable
recruitment of GFP‐labelled β‐arrestin 2 to the plasma membrane in
δ‐receptor‐expressing HEK cells.
Comparing β‐arrestin recruitment using the PRESTO‐TANGO
assay with GTPγ35S binding, we find DPDPE to be G‐protein biased
at δ‐receptors expressed in HEK cells, relative to SNC80. This agrees
with studies that indicate SNC80 is a “super recruiter” of β‐arrestin
2, compared with DPDPE, at δ‐receptors in CHO cells, whereas both
have similar activity as inhibitors of AC (Chiang et al., 2016) and with
predictions from studies in vivo that SNC80 is a “high‐internalizing
agonist” when compared with the low‐internalizing δ‐receptor agonist
ARM390 and partial agonists such as TAN‐67 (Pradhan et al., 2009,
2010; Pradhsan et al., 2012). In contrast, bias calculations (Charfi,
Audet, Bagheri Tudashki, & Pineyro, 2015) based on data obtained
at the δ‐receptors expressed in HEK cells (Charfi et al., 2013) suggest
SNC80 is highly biased towards AC inhibition, relative tointernalization, when compared with DPDPE, although these data also
show that SNC80 recruits much more β‐arrestin than DPDPE. Overall,
these findings highlight the importance of understanding the relativity
of bias, where the chosen reference ligand can have a significant influ-
ence on the direction, magnitude, and interpretation of observed
results. Here, we chose to use SNC80 as a reference ligand as it is a
“standard” δ‐receptor ligand characterized in many in vitro and behav-
ioural assays (Chung et al., 2015; Danielsson et al., 2006; Dripps et al.,
2017; Jutkiewicz et al., 2005; Pradhan et al., 2010). On the other hand,
we have shown DPDPE to be 11‐fold biased towards G‐protein, rela-
tive to β‐arrestin recruitment, using SNC80 as a reference. Conse-
quently, if DPDPE is used as a reference ligand, the bias of BMS
986187 towards G‐protein activation is reduced to ninefold.
BMS 986187 also failed to produce δ‐receptor‐mediated phos-
phorylation of ERK1/ERK2 in the MAPK pathway, although it showed
significant G‐protein activation. This implies phosphorylation of
ERK1/ERK2 via the allosteric site on δ‐receptors may be a β‐arrestin
2‐mediated process, a ligand‐dependent effect observed at other
GPCRs (Shukla et al., 2008). However, this contrasts with the finding
that BMS 986187 when acting as a PAM for δ‐receptors promotes
ERK1/ERK2 phosphorylation (Burford, Livingston, et al., 2015; Burford,
Traynor, & Alt, 2015). These apparently conflicting data imply that the
BMS 986187‐occupied δ‐receptors may signal differently depending
on whether or not the orthosteric site is occupied. We are currently
investigating the effect of BMS 986187 on ERK1/ERK2 phosphoryla-
tion using a variety of δ‐receptor agonists. PAM activity arises at opioid
receptors by a negative, indirect action with the Na+ ion‐binding site.
Na+ holds the receptor in inactive conformations (R), and loss of Na+
ion binding allows the receptor to adopt ensembles of active receptor
(R*) states (Liu et al., 2012; Livingston & Traynor, 2014; Pert, Pasternak,
& Snyder, 1973). PAMswith greater efficacy to displace Na+ ions would
then be predicted to show allosteric agonism by the same process.
However, driving receptor activation through an allosteric site, there
is no a priori reason why an allosteric agonist could not show functional
selectivity at δ‐receptors by promoting a different ensemble of R*
conformations from that promoted by an orthosteric ligand. Indeed,
such an effect has been observed at the muscarinic ACh receptor
where allosteric agonists promoted bias, comparing G‐protein
activation and ERK1/ERK2 phosphorylation (Gregory, Hall, Tobin,
Sexton, & Christopoulos, 2010).
Recruitment of β‐arrestin and δ‐receptor internalization
requires sequential phosphorylation of several Ser and Thr residues
in the C‐terminal tail of the receptor by G‐protein receptor kinases
(Ferguson, 2001; Qiu et al., 2007; Stoffel, Pitcher, & Lefkowitz,
1997). Mutagenesis studies have indicated that an important initial
phosphorylation site in the δ‐receptor phosphorylation cascade is
Ser363 (El Kouhen et al., 2000). BMS 986187 produced a low level
of Ser363 phosphorylation, compared with DPDPE and SNC80, and
similar to the low‐internalizing agonist TAN‐67. This explains why
the allosteric agonist induces significantly less desensitization than
SNC80. However, it is perhaps surprising given the low level of phos-
phorylation and β‐arrestin recruitment that BMS 986187 caused δ‐
receptor desensitization. It is possible that over extended periods,
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986187 is able to drive significant desensitization. Alternatively, the
BMS 986187‐occupied δ‐receptor is in different conformational
states from those in orthosteric agonist‐occupied δ‐receptors and so
may employ different desensitization mechanisms. In this regard, it
should be noted that mutants of δ‐receptors expressed in HEK cells
showing no detectable phosphorylation still desensitize over time (El
Kouhen et al., 2000). Nonetheless, the low level of phosphorylation
observed establishes that the bias driven by BMS 986187 results
from reduced phosphorylation of the receptor, even though BMS
986187 does recruit G‐protein and presumably G‐protein receptor
kinases. This signifies that the δ‐receptor conformations induced in
the presence of BMS 986187 differ from those adopted in the
presence of SNC80. A greater understanding of these conformations
would provide insight into the driving force behind G‐protein versus β‐
arrestin‐mediated signalling for both orthosteric and allosteric ligands.
In conclusion, BMS 986187 is a biased allosteric agonist of the δ‐
receptor. Biased allosteric agonism at δ‐receptors could represent a
novel strategy for treating chronic pain and depression, while poten-
tially avoiding limiting factors such as rapid tolerance development
and induction of convulsions.
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